| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
36,651,000 |
| Market
Cap: |
570.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.84 - $28.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Quanterix is a life sciences company that has developed digital immunoassay platforms. Co.'s platforms are based on its proprietary digital Simoa detection technology. Co. provides the following three Simoa instruments: HD-X, which is based on Co.'s bead-based technology, and assays run on the HD-X are fully automated; SR-X, which utilizes the same Simoa bead-based technology and assay kits as the HD-X in a compact benchtop form with a range of applications; and SP-X, which is based on Co.'s planar array technology, which allows for multiplexing capabilities for oncology and immunology applications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
20,200 |
639,331 |
| Total Buy Value |
$0 |
$0 |
$501,978 |
$6,053,841 |
| Total People Bought |
0 |
0 |
1 |
7 |
| Total Buy Transactions |
0 |
0 |
1 |
8 |
| Total Shares Sold |
2,500 |
5,000 |
5,000 |
10,265 |
| Total Sell Value |
$60,025 |
$119,770 |
$119,770 |
$214,084 |
| Total People Sold |
1 |
1 |
1 |
5 |
| Total Sell Transactions |
2 |
4 |
4 |
15 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-08-03 |
4 |
S |
$53.79 |
$196,219 |
D/D |
(3,648) |
933,619 |
|
26% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-08-03 |
4 |
S |
$53.79 |
$18,611 |
D/D |
(346) |
37,543 |
|
26% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-07-29 |
4 |
AS |
$53.81 |
$270,420 |
D/D |
(5,000) |
937,267 |
|
-22% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2021-07-14 |
4 |
AS |
$57.77 |
$96,303 |
D/D |
(1,667) |
31,617 |
|
-13% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-07-13 |
4 |
AS |
$57.22 |
$287,265 |
D/D |
(5,000) |
942,267 |
|
-14% |
|
| Doyle Michael A |
CFO and Treasurer |
• – – |
2021-07-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,530 |
5,530 |
|
- |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2021-07-02 |
4 |
S |
$57.64 |
$20,199 |
D/D |
(346) |
34,043 |
|
6% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2021-07-02 |
4 |
S |
$57.64 |
$8,524 |
D/D |
(146) |
23,990 |
|
6% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-07-02 |
4 |
AS |
$57.64 |
$20,256 |
D/D |
(347) |
37,889 |
|
-6% |
|
| Hrusovsky E Kevin |
Chairman, President & CEO |
• • – |
2021-07-02 |
4 |
S |
$57.64 |
$213,543 |
D/D |
(3,658) |
947,267 |
|
6% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-07-01 |
4 |
AS |
$58.07 |
$493,764 |
D/D |
(8,454) |
38,236 |
|
-3% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-07-01 |
4 |
OE |
$22.12 |
$216,909 |
D/D |
9,806 |
46,690 |
|
- |
|
| Mcconnell Sarah H |
|
– • – |
2021-07-01 |
4 |
A |
$59.48 |
$11,837 |
D/D |
199 |
11,660 |
|
- |
|
| Madaus Martin D |
|
– • – |
2021-07-01 |
4 |
A |
$59.48 |
$18,082 |
D/D |
304 |
14,994 |
|
- |
|
| Olson Laurie J |
|
– • – |
2021-07-01 |
4 |
A |
$59.48 |
$6,186 |
D/D |
104 |
4,644 |
|
- |
|
| Crandell Keith |
Director |
– • – |
2021-07-01 |
4 |
A |
$59.48 |
$12,967 |
D/D |
218 |
75,852 |
|
- |
|
| Meister Paul M |
|
– • – |
2021-07-01 |
4 |
A |
$59.48 |
$13,740 |
D/D |
231 |
13,661 |
|
- |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2021-06-23 |
4 |
AS |
$62.11 |
$103,537 |
D/D |
(1,667) |
33,284 |
|
-20% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-06-15 |
4 |
AS |
$64.33 |
$44,776 |
D/D |
(696) |
36,884 |
|
-22% |
|
| Toloue Masoud |
President, Quanterix & Dx |
• – – |
2021-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
50,703 |
50,703 |
|
- |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-06-07 |
4 |
AS |
$57.00 |
$805,623 |
D/D |
(13,549) |
37,580 |
|
-19% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-06-07 |
4 |
OE |
$19.12 |
$405,579 |
D/D |
18,396 |
51,129 |
|
- |
|
| Dekkers Marijn E |
|
– • – |
2021-06-07 |
4 |
AS |
$55.58 |
$506,160 |
D/D |
(9,051) |
2,270 |
|
-19% |
|
| Dekkers Marijn E |
|
– • – |
2021-06-07 |
4 |
OE |
$23.12 |
$109,404 |
D/D |
4,732 |
11,321 |
|
- |
|
| Dekkers Marijn E |
|
– • – |
2021-06-04 |
4 |
AS |
$55.05 |
$418,918 |
D/D |
(7,610) |
6,589 |
|
-14% |
|
278 Records found
|
|
Page 5 of 12 |
|
|
0.03 (0.19%) 
